RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Rating) shares gapped down before the market opened on Tuesday following insider selling activity. The stock had previously closed at $26.61, but opened at $24.55. RAPT Therapeutics shares last traded at $20.56, with a volume of 454,726 shares traded.
Specifically, insider William Ho sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 24th. The stock was sold at an average price of $30.00, for a total value of $150,000.00. Following the completion of the sale, the insider now owns 30,072 shares of the company’s stock, valued at approximately $902,160. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders have sold a total of 20,742 shares of company stock valued at $532,352 in the last 90 days. 5.00% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
Several equities research analysts have weighed in on the stock. The Goldman Sachs Group assumed coverage on shares of RAPT Therapeutics in a research report on Thursday, December 1st. They issued a “buy” rating and a $27.00 price objective for the company. Guggenheim initiated coverage on shares of RAPT Therapeutics in a report on Wednesday, January 4th. They set a “buy” rating and a $55.00 price objective for the company. Piper Sandler cut their price target on shares of RAPT Therapeutics from $34.00 to $33.00 in a research note on Thursday, December 8th. Finally, Wells Fargo & Company cut their price objective on shares of RAPT Therapeutics from $55.00 to $48.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 4th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, RAPT Therapeutics currently has an average rating of “Buy” and a consensus target price of $44.14.
RAPT Therapeutics Trading Down 26.0 %
Hedge Funds Weigh In On RAPT Therapeutics
Hedge funds have recently modified their holdings of the company. Alliancebernstein L.P. raised its stake in RAPT Therapeutics by 10.0% in the fourth quarter. Alliancebernstein L.P. now owns 30,900 shares of the company’s stock worth $612,000 after buying an additional 2,800 shares in the last quarter. Trustees of Columbia University in the City of New York bought a new stake in shares of RAPT Therapeutics during the fourth quarter valued at approximately $1,453,000. State of Wisconsin Investment Board boosted its holdings in RAPT Therapeutics by 18.8% in the fourth quarter. State of Wisconsin Investment Board now owns 28,774 shares of the company’s stock worth $570,000 after purchasing an additional 4,552 shares during the last quarter. Schonfeld Strategic Advisors LLC boosted its stake in shares of RAPT Therapeutics by 165.2% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 281,875 shares of the company’s stock worth $5,581,000 after acquiring an additional 175,585 shares during the last quarter. Finally, Legal & General Group Plc raised its position in shares of RAPT Therapeutics by 14.1% during the 4th quarter. Legal & General Group Plc now owns 10,278 shares of the company’s stock valued at $204,000 after purchasing an additional 1,268 shares during the period.
About RAPT Therapeutics
Rapt Therapeutics, Inc operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.
- Get a free copy of the StockNews.com research report on RAPT Therapeutics (RAPT)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.